|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NECTIN4 |
Gene summary for NECTIN4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NECTIN4 | Gene ID | 81607 |
| Gene name | nectin cell adhesion molecule 4 | |
| Gene Alias | EDSS1 | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | K4PZ75 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 81607 | NECTIN4 | sample3 | Human | Cervix | CC | 3.86e-46 | 6.93e-01 | 0.1387 |
| 81607 | NECTIN4 | H2 | Human | Cervix | HSIL_HPV | 5.64e-06 | 3.36e-01 | 0.0632 |
| 81607 | NECTIN4 | L1 | Human | Cervix | CC | 5.25e-16 | 7.09e-01 | 0.0802 |
| 81607 | NECTIN4 | T1 | Human | Cervix | CC | 5.25e-06 | 2.02e-01 | 0.0918 |
| 81607 | NECTIN4 | T3 | Human | Cervix | CC | 6.85e-34 | 6.75e-01 | 0.1389 |
| 81607 | NECTIN4 | LZE4T | Human | Esophagus | ESCC | 8.26e-16 | 6.11e-01 | 0.0811 |
| 81607 | NECTIN4 | LZE5T | Human | Esophagus | ESCC | 3.62e-07 | 6.25e-01 | 0.0514 |
| 81607 | NECTIN4 | LZE7T | Human | Esophagus | ESCC | 2.99e-02 | 2.43e-01 | 0.0667 |
| 81607 | NECTIN4 | LZE8T | Human | Esophagus | ESCC | 7.15e-03 | 1.74e-01 | 0.067 |
| 81607 | NECTIN4 | LZE20T | Human | Esophagus | ESCC | 5.02e-07 | 3.46e-01 | 0.0662 |
| 81607 | NECTIN4 | LZE22T | Human | Esophagus | ESCC | 3.08e-04 | 7.26e-01 | 0.068 |
| 81607 | NECTIN4 | LZE24T | Human | Esophagus | ESCC | 5.48e-19 | 6.97e-01 | 0.0596 |
| 81607 | NECTIN4 | LZE21T | Human | Esophagus | ESCC | 1.00e-10 | 9.77e-01 | 0.0655 |
| 81607 | NECTIN4 | male-WTA | Human | Thyroid | PTC | 5.43e-04 | 7.48e-02 | 0.1037 |
| 81607 | NECTIN4 | PTC01 | Human | Thyroid | PTC | 5.43e-04 | 1.22e-01 | 0.1899 |
| 81607 | NECTIN4 | PTC05 | Human | Thyroid | PTC | 1.58e-22 | 7.47e-01 | 0.2065 |
| 81607 | NECTIN4 | PTC06 | Human | Thyroid | PTC | 3.43e-26 | 7.26e-01 | 0.2057 |
| 81607 | NECTIN4 | PTC07 | Human | Thyroid | PTC | 1.19e-10 | 2.28e-01 | 0.2044 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00160329 | Breast | Precancer | viral process | 58/1080 | 415/18723 | 3.42e-10 | 3.16e-08 | 58 |
| GO:00190589 | Breast | Precancer | viral life cycle | 47/1080 | 317/18723 | 2.42e-09 | 1.99e-07 | 47 |
| GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
| GO:00521269 | Breast | Precancer | movement in host environment | 29/1080 | 175/18723 | 2.59e-07 | 1.28e-05 | 29 |
| GO:00517019 | Breast | Precancer | biological process involved in interaction with host | 31/1080 | 203/18723 | 6.52e-07 | 2.71e-05 | 31 |
| GO:00444099 | Breast | Precancer | entry into host | 25/1080 | 151/18723 | 1.74e-06 | 6.19e-05 | 25 |
| GO:00467189 | Breast | Precancer | viral entry into host cell | 24/1080 | 144/18723 | 2.46e-06 | 8.35e-05 | 24 |
| GO:001603214 | Breast | IDC | viral process | 75/1434 | 415/18723 | 1.98e-12 | 4.02e-10 | 75 |
| GO:001905814 | Breast | IDC | viral life cycle | 61/1434 | 317/18723 | 1.61e-11 | 2.77e-09 | 61 |
| GO:004440314 | Breast | IDC | biological process involved in symbiotic interaction | 52/1434 | 290/18723 | 6.55e-09 | 5.03e-07 | 52 |
| GO:005212614 | Breast | IDC | movement in host environment | 32/1434 | 175/18723 | 3.33e-06 | 1.22e-04 | 32 |
| GO:005170114 | Breast | IDC | biological process involved in interaction with host | 35/1434 | 203/18723 | 4.72e-06 | 1.63e-04 | 35 |
| GO:004440914 | Breast | IDC | entry into host | 28/1434 | 151/18723 | 1.02e-05 | 2.82e-04 | 28 |
| GO:004671814 | Breast | IDC | viral entry into host cell | 27/1434 | 144/18723 | 1.18e-05 | 3.14e-04 | 27 |
| GO:001603224 | Breast | DCIS | viral process | 73/1390 | 415/18723 | 3.40e-12 | 6.88e-10 | 73 |
| GO:001905824 | Breast | DCIS | viral life cycle | 59/1390 | 317/18723 | 4.05e-11 | 5.74e-09 | 59 |
| GO:004440323 | Breast | DCIS | biological process involved in symbiotic interaction | 49/1390 | 290/18723 | 4.70e-08 | 2.89e-06 | 49 |
| GO:005212624 | Breast | DCIS | movement in host environment | 31/1390 | 175/18723 | 4.93e-06 | 1.45e-04 | 31 |
| GO:005170124 | Breast | DCIS | biological process involved in interaction with host | 34/1390 | 203/18723 | 6.30e-06 | 1.78e-04 | 34 |
| GO:004440924 | Breast | DCIS | entry into host | 27/1390 | 151/18723 | 1.65e-05 | 4.00e-04 | 27 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0452018 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
| hsa0452019 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
| hsa0452020 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
| hsa04520110 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
| hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
| hsa04520114 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| NECTIN1 | NECTIN4 | NECTIN1_NECTIN4 | NECTIN | Cervix | CC |
| NECTIN1 | NECTIN4 | NECTIN1_NECTIN4 | NECTIN | CRC | MSI-H |
| NECTIN1 | NECTIN4 | NECTIN1_NECTIN4 | NECTIN | Prostate | BPH |
| NECTIN1 | NECTIN4 | NECTIN1_NECTIN4 | NECTIN | Prostate | Healthy |
| NECTIN1 | NECTIN4 | NECTIN1_NECTIN4 | NECTIN | Skin | ADJ |
| NECTIN1 | NECTIN4 | NECTIN1_NECTIN4 | NECTIN | Skin | AK |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NECTIN4 | SNV | Missense_Mutation | rs558365881 | c.1261G>C | p.Glu421Gln | p.E421Q | Q96NY8 | protein_coding | deleterious(0.04) | possibly_damaging(0.676) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| NECTIN4 | SNV | Missense_Mutation | c.619G>C | p.Glu207Gln | p.E207Q | Q96NY8 | protein_coding | tolerated(0.08) | probably_damaging(0.996) | TCGA-D8-A1JC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| NECTIN4 | SNV | Missense_Mutation | c.71N>T | p.Ser24Leu | p.S24L | Q96NY8 | protein_coding | deleterious(0.03) | possibly_damaging(0.879) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD | |
| NECTIN4 | SNV | Missense_Mutation | c.1171N>G | p.Thr391Ala | p.T391A | Q96NY8 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| NECTIN4 | SNV | Missense_Mutation | c.242N>G | p.Leu81Arg | p.L81R | Q96NY8 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NECTIN4 | SNV | Missense_Mutation | c.418C>T | p.Arg140Trp | p.R140W | Q96NY8 | protein_coding | deleterious(0.01) | probably_damaging(0.914) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| NECTIN4 | insertion | Frame_Shift_Ins | novel | c.1224_1225insC | p.Arg409GlnfsTer17 | p.R409Qfs*17 | Q96NY8 | protein_coding | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| NECTIN4 | SNV | Missense_Mutation | rs371363602 | c.1046N>T | p.Ser349Leu | p.S349L | Q96NY8 | protein_coding | tolerated(1) | probably_damaging(0.978) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NECTIN4 | SNV | Missense_Mutation | rs267606991 | c.851N>A | p.Arg284Gln | p.R284Q | Q96NY8 | protein_coding | tolerated(0.06) | probably_damaging(0.994) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NECTIN4 | SNV | Missense_Mutation | c.665N>T | p.Thr222Ile | p.T222I | Q96NY8 | protein_coding | deleterious(0.04) | probably_damaging(0.998) | TCGA-A5-A0GA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 81607 | NECTIN4 | DRUGGABLE GENOME | antibody | 405067331 | ||
| 81607 | NECTIN4 | DRUGGABLE GENOME | ASG-22ME | ENFORTUMAB VEDOTIN | ||
| 81607 | NECTIN4 | DRUGGABLE GENOME | ENFORTUMAB VEDOTIN | 27013195 | ||
| 81607 | NECTIN4 | DRUGGABLE GENOME | ASG-22ME | ENFORTUMAB VEDOTIN | ||
| 81607 | NECTIN4 | DRUGGABLE GENOME | antibody | AGS-22M6E | ENFORTUMAB VEDOTIN | |
| 81607 | NECTIN4 | DRUGGABLE GENOME | enfortumab vedotin | |||
| 81607 | NECTIN4 | DRUGGABLE GENOME | Enfortumab Vedotin-ejfv |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |